1)Herbrecht R, Denning DW, Patterson TF et al:Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415, 2002
2)Scherer WJ, Lee K:Implications of early systemic therapy on the incidence of endogenous fungal endophthalmitis. Ophthalmology 104:1593-1598, 1997
3)前崎繁文:真菌によるセプシス.治療学 40:505-508,2006
4)竹末芳生・大毛宏喜:内因性真菌性眼内炎.過去から現在へ.化学療法の領域 21:983-986,2005
5)Hariprasad SM, Mieler WF, Holz ER et al:Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 122:42-47, 2004
6)Marangon FB, Miller D, Giaconi JA et al:In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 137:820-825, 2004
7)Sen P, Gopal L, Sen PR:Intravitreal voriconazole for drug-resistant fungal endophthalmitis:case series. Retina 26:935-939, 2006
8)Gao H, Pennesi ME, Shah K et al:Intravitreal voriconazole:an electroretinographic and histopathologic study. Arch Ophthalmol 122:1687-1692, 2004